Literature DB >> 24131380

Predictive value of selected biomarkers, polymorphisms, and clinical features for oligoarticular juvenile idiopathic arthritis-associated uveitis.

Laura Pelegrín1, Ricardo Casaroli-Marano, Jordi Antón, María Carmen García de Vicuña, Nicolás Molina-Prat, Juan Ignacio Aróstegui, Jordi Yagüe, José Ríos, Alfredo Adán.   

Abstract

PURPOSE: Uveitis is the most common extra-articular manifestation of juvenile idiopathic arthritis (JIA) and is associated with considerable morbidity. The aim of this study was to examine the risk factors associated with uveitis in oligoarticular JIA.
METHODS: We conducted a chart review of 86 patients with oligoarticular JIA to assess if antinuclear antibody (ANA) status, gender, and age at JIA onset were associated with the development of uveitis. Biomarkers such as cytokine gene polymorphisms, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) level were also assessed.
RESULTS: Twenty-seven patients exhibited oligoarticular JIA-associated uveitis. Only the ESR at arthritis onset and the patient's age at arthritis onset were related to uveitis development in our patient sample.
CONCLUSIONS: An age-associated risk of uveitis was observed in children younger than 3 years at the time of JIA onset. ESR values at arthritis onset higher than 22 mm/h were also related to uveitis development.

Entities:  

Keywords:  Age of arthritis onset; chronic anterior uveitis; erythrocyte sedimentation rate; oligoarticular juvenile idiopathic arthritis; polymorphism

Mesh:

Substances:

Year:  2013        PMID: 24131380     DOI: 10.3109/09273948.2013.841495

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  7 in total

Review 1.  Uveitis associated with juvenile idiopathic arthritis.

Authors:  Ethan S Sen; Andrew D Dick; Athimalaipet V Ramanan
Journal:  Nat Rev Rheumatol       Date:  2015-03-31       Impact factor: 20.543

2.  High-sensitive CRP as a predictive marker of long-term outcome in juvenile idiopathic arthritis.

Authors:  Mikel Alberdi-Saugstrup; Marek Zak; Susan Nielsen; Troels Herlin; Ellen Nordal; Lillemor Berntson; Anders Fasth; Marite Rygg
Journal:  Rheumatol Int       Date:  2017-03-10       Impact factor: 2.631

Review 3.  Treatment of uveitis associated with juvenile idiopathic arthritis.

Authors:  Rosa Bou; Estíbaliz Iglesias; Jordi Antón
Journal:  Curr Rheumatol Rep       Date:  2014-08       Impact factor: 4.592

4.  Risk Factors and Biomarkers for the Occurrence of Uveitis in Juvenile Idiopathic Arthritis: Data From the Inception Cohort of Newly Diagnosed Patients With Juvenile Idiopathic Arthritis Study.

Authors:  Christoph Tappeiner; Jens Klotsche; Claudia Sengler; Martina Niewerth; Ina Liedmann; Karoline Walscheid; Miha Lavric; Dirk Foell; Kirsten Minden; Arnd Heiligenhaus
Journal:  Arthritis Rheumatol       Date:  2018-08-21       Impact factor: 10.995

5.  Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative.

Authors:  Tamas Constantin; Ivan Foeldvari; Jordi Anton; Joke de Boer; Severine Czitrom-Guillaume; Clive Edelsten; Raz Gepstein; Arnd Heiligenhaus; Clarissa A Pilkington; Gabriele Simonini; Yosef Uziel; Sebastian J Vastert; Nico M Wulffraat; Anne-Mieke Haasnoot; Karoline Walscheid; Annamária Pálinkás; Reshma Pattani; Zoltán Györgyi; Richárd Kozma; Victor Boom; Andrea Ponyi; Angelo Ravelli; Athimalaipet V Ramanan
Journal:  Ann Rheum Dis       Date:  2018-03-28       Impact factor: 19.103

6.  Impact of Antiinflammatory Treatment on the Onset of Uveitis in Juvenile Idiopathic Arthritis: Longitudinal Analysis From a Nationwide Pediatric Rheumatology Database.

Authors:  Christoph Tappeiner; Sandra Schenck; Martina Niewerth; Arnd Heiligenhaus; Kirsten Minden; Jens Klotsche
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-01       Impact factor: 4.794

7.  Re: oligoarticular juvenile idiopathic arthritis among Saudi children.

Authors:  Mahmood D Al-Mendalawi
Journal:  Ann Saudi Med       Date:  2014 Mar-Apr       Impact factor: 1.526

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.